Sugemalimab Clinical Trials

3 actively recruiting trials

Also known as: Programmed Death Ligand-1 (PD-L1) Inhibitor

Pipeline

Phase 3: 1Phase 1/2: 1Phase 2/3: 1

Top Sponsors

Sun Yat-sen University1
Sichuan University1
Akeso1

Indications

Lung Cancer3
Cancer3
Limited Stage Small Cell Lung Cancer1
NSCLC (Non-small Cell Lung Cancer)1
Extensive Stage-small Cell Lung Cancer1

Other3 trials

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Phase 3

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.